Black Rock Inc. Otonomy, Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.25 - $2.24 $1,037 - $9,293	-4,149 Reduced 0.52%	786,672 $232,000
Q2 2022 Aug 12, 2022	SELL	$1.72 - $2.51 $17,172 - $25,059	-9,984 Reduced 1.25%	790,821 $1.65 Million
Q1 2022 May 12, 2022	SELL	$1.72 - $2.47 $8,854 - $12,715	-5,148 Reduced 0.64%	800,805 $1.92 Million
Q4 2021 Feb 10, 2022	BUY	$1.69 - $2.31 $11,674 - $15,957	6,908 Added 0.86%	805,953 $1.68 Million
Q3 2021 Nov 09, 2021	SELL	$1.22 - $2.2 $16,532 - $29,812	-13,551 Reduced 1.67%	799,045 $1.53 Million
Q2 2021 Aug 11, 2021	BUY	$2.06 - $2.67 $1.67 Million - $2.17 Million	812,596 New	812,596 $1.81 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.